This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simoneau, A. R. Articles by Meyskens, F. L. Search for Related Content PubMed PubMed Citation Articles by Simoneau, A. R. Articles by Meyskens, F. L., Jr. Related Collections Clinical Intervention Clinical Intervention: Biomarkers Clinical Intervention: Early-Phase (I/II) Clinical or Translational Trials

The Effect of Difluoromethylornithine on Decreasing Prostate Size and Polyamines in Men: Results of a Year-Long Phase IIb Randomized Placebo-Controlled Chemoprevention Trial

Departments of ¹ Medicine, ² Urology, and ³ Epidemiology and ⁴ Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California; ⁵ University of Arizona, Tucson, Arizona; and ⁶ Department of Chemoprevention Investigational Branch, Bethesda, Maryland

Requests for reprints: Anne R. Simoneau, University of California, Irvine, 101 The City Drive, Route 81, Building 55, Room 304, Orange, CA 92868. Phone: 714-456-3330; Fax: 714-456-5062. E-mail: asimonea{at}uci.edu

Background: Prostate cancer is a major health issue, and prevention of prostate cancer and/or its progression will yield benefits for men. Difluoromethylornithine (DFMO) is an antiproliferative agent, inhibiting ornithine decarboxylase, the first enzyme in the polyamine pathway, and has been studied as a therapeutic and chemopreventive agent. The prostate has high levels of tissue polyamines and has shown sensitivity to DFMO both in vitro and in vivo.

Methods: Eighty-one men participated in a 1-year randomized trial of placebo or DFMO. Prostate volume determination and biopsy of the prostate for histology and polyamine content were done at baseline and after 12 months. Other biomarker variables were assessed, including total and free prostate-specific antigen and prostate-specific antigen doubling time.

Results: Compared with baseline, men receiving DFMO had a smaller increase in prostate volume (0.14 cm³) than those on placebo (2.95 cm³; P = 0.0301) at 1 year. In addition, DFMO caused a 60.8% reduction of prostate putrescine levels compared with a 139.5% increase in the placebo arm (P = 0.0014). Stratification by ornithine decarboxylase genotype showed that DFMO reduced prostate volume (P = 0.029) and putrescine levels (P = 0.0053) in the AA + GA group but not in the GG group. There were no grade 3 or 4 toxicities. There was no clinical ototoxicity, with one subclinical grade 2 hearing decline on audiogram.

Conclusion: In this randomized placebo-controlled trial, DFMO induced a decrease of prostate putrescine levels and rate of prostate growth. The potential of this compound for prostate cancer or hyperplasia should be further studied. (Cancer Epidemiol Biomarkers Prev 2008;17(2):292–9)

This article has been cited by other articles:

				N. A. IGNATENKO, H. F. YERUSHALMI, R. PANDEY, K. L. KACHEL, D. E. STRINGER, L. J. MARTON, and E. W. GERNER Gene Expression Analysis of HCT116 Colon Tumor-derived Cells Treated with the Polyamine Analog PG-11047 Cancer Genomics Proteomics, May 1, 2009; 6(3): 161 - 175. [Abstract] [Full Text] [PDF]

				R. J. Rounbehler, W. Li, M. A. Hall, C. Yang, M. Fallahi, and J. L. Cleveland Targeting Ornithine Decarboxylase Impairs Development of MYCN-Amplified Neuroblastoma Cancer Res., January 15, 2009; 69(2): 547 - 553. [Abstract] [Full Text] [PDF]

				X. Wang, S. Levic, M. A. Gratton, K. J. Doyle, E. N. Yamoah, and A. E. Pegg Spermine Synthase Deficiency Leads to Deafness and a Profound Sensitivity to {alpha}-Difluoromethylornithine J. Biol. Chem., January 9, 2009; 284(2): 930 - 937. [Abstract] [Full Text] [PDF]